Protagonist Therapeutics, Inc (18)
Browse by Contract Category
Contracts
-
Description of Protagonist Therapeutics, Inc.s Securities Registered Pursuant to Section 12 of the Exchange Act
(Filed With SEC on February 28, 2022)
-
Second Amendment to Lease, dated August 10, 2021, by and between Protagonist Therapeutics, Inc., as Tenant, and BMR-Pacific Research Center, LP as Landlord
(Filed With SEC on November 3, 2021)
-
Second Amendment to the Exclusive Janssen License and Collaboration Agreement, dated July 27, 2021, by and between Protagonist Therapeutics, Inc. and Janssen Biotech, Inc
(Filed With SEC on November 3, 2021)
-
Underwriting Agreement, dated June 15, 2021
(Filed With SEC on June 17, 2021)
-
Severance Agreement, dated August 4, 2020, by and between Protagonist Therapeutics, Inc. and Don Kalkofen
(Filed With SEC on August 6, 2020)
-
Arbitration Resolution Agreement, dated August 4th, 2021, by and among Protagonist Therapeutics, Inc. and Zealand Pharma, A/S
(Filed With SEC on November 3, 2021)
-
Description of Protagonist Therapeutics, Inc.s Securities Registered Pursuant to Section 12 of the Exchange Act
(Filed With SEC on March 10, 2021)
-
Underwriting Agreement, dated December 10, 2020
(Filed With SEC on December 11, 2020)
-
Underwriting Agreement, dated as of May 11, 2020
(Filed With SEC on May 12, 2020)
-
Description of Protagonist Therapeutics, Inc.s Securities Registered Pursuant to Section 12 of the Exchange Act
(Filed With SEC on March 10, 2020)
-
Protagonist Therapeutics, Inc. Amended and Restated 2018 Inducement Plan
(Filed With SEC on February 24, 2020)
-
Open Market Sale AgreementSM, dated November 27, 2019, by and between Protagonist Therapeutics, Inc. and Jefferies LLC
(Filed With SEC on November 27, 2019)
-
Severance Agreement, dated July 19, 2019, by and between Protagonist Therapeutics, Inc. and Samuel Saks, M.D
(Filed With SEC on November 6, 2019)
-
First Amendment to Exclusive License and Collaboration Agreement, by and between Protagonist Therapeutics, Inc. and Janssen Biotech, Inc., dated May 7, 2019
(Filed With SEC on August 7, 2019)
-
Offer Letter between Protagonist Therapeutics, Inc. and Donald Kalkofen, dated May 20, 2019
(Filed With SEC on May 29, 2019)
-
Separation Agreement between Protagonist Therapeutics, Inc. and Richard S. Shames, dated May 7, 2019
(Filed With SEC on May 13, 2019)
-
Severance Agreement, dated March 14, 2019, by and among Protagonist Therapeutics, Inc. and Suneel Gupta, Ph.D
(Filed With SEC on May 8, 2019)
-
First Amendment, dated January 31, 2019, to Lease, dated March 6, 2017, by and between Protagonist Therapeutics, Inc., as Tenant, and BMR-Pacific Research Center LP
(Filed With SEC on May 8, 2019)